Botox Injections May Ease Depression
An FDA database revealed that people who receive Botox injections report less depression.
Migraine and Headache
Atogepant Reduces Monthly Migraine Days in Phase 3 Prevention Trial
The ADVANCE study included 910 adults who experienced 4 to 14 migraines per month.
Managing Chronic Headache During the COVID-19 Pandemic: A Q&A
Matthew Robbins, MD, author of “COVID-19 and headache: a primer for trainees,” details how care has changed for patients with chronic headaches in the midst of the COVID-19 pandemic.
Positive Outcomes Reported With Novel Intranasal DHE for Migraine
Positive results were announced from the phase 3 STOP-301 study evaluating INP104 (intranasal dihydroergotamine mesylate; Impel NeuroPharma) for the treatment of acute migraine in adults.
Galcanezumab Linked to Improved Work Productivity in Patients With Migraine
Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
MPR Weekly Dose Podcast Episode 33
This week we cover the the risk of antihypertensive med use during the pandemic; The Emergency Use Authorization for remdesivir in hospitalized patients with suspected or confirmed COVID-19; The addition of a Boxed Warning to Montelukast; A new Farxiga indication; And a novel treatment for acute migraines.
Celecoxib Oral Solution Approved for Acute Migraine Treatment
The FDA has approved Elyxyb (Dr. Reddy’s Laboratories), an oral solution formulation of celecoxib, for the acute treatment of migraine with or without aura in adults.
Ajovy Now Available in Autoinjector Device for Migraine Prevention
Ajovy (fremanezumab-vfrm; Teva) is now available in an autoinjector device for the preventive treatment of migraine in adults.
New Drug Product: Vyepti
This slideshow shows drug information for Vyepti. Click here for the complete Vyepti monograph.
New Drug Product: Nurtec ODT
This slideshow shows drug information for Nurtec ODT. Click here for the complete Nurtec ODT monograph.
